Prestige Consumer Healthcare
PBH
Market cap $4.15B

83.97 USD

-1.17

1.37%

At close Jun 13, 4:00 PM EDT

After hours

83.97

+0.00

0.00%

1 day

-1.37%

5 days

-1.42%

1 month

-3.45%

3 months

1.38%

6 months

2.03%

Year to date

8.04%

1 year

29.50%

5 years

108.72%

10 years

86.35%

About: Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Employees: 600

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

117% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 23

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 4 (+2) [Q1 2025]

7% more capital invested

Capital invested by funds: $4.1B [Q4 2024] → $4.4B (+$299M) [Q1 2025]

7% more funds holding

Funds holding: 334 [Q4 2024] → 356 (+22) [Q1 2025]

2.93% less ownership

Funds ownership: 106.18% [Q4 2024] → 103.25% (-2.93%) [Q1 2025]

31% less repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 153

79% less call options, than puts

Call options by funds: $9K | Put options by funds: $43K

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$97

16%

upside

Avg. target

$97

16%

upside

High target

$97

16%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

RBC Capital

16%upside

$97

Sector Perform

Maintained

21 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about PBH published over the past 30 days

Zacks Investment Research

Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?

PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.

Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?

Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference

TARRYTOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on Wednesday, June 11, 2025 at 10:30 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:

Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference

Zacks Investment Research

PBH vs. SYK: Which Stock Is the Better Value Option?

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

PBH vs. SYK: Which Stock Is the Better Value Option?

Zacks Investment Research

Prestige Consumer Gains 35.7% in a Year: What's Driving the Stock?

PBH stock jumps on the back of brand strength, e-commerce gains and smart acquisitions despite tariff and foreign exchange headwinds.

Prestige Consumer Gains 35.7% in a Year: What's Driving the Stock?

Zacks Investment Research

PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?

PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase

PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.

Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase

Prestige Consumer Healthcare Inc. (PBH) Q4 2025 Earnings Call Transcript

Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q4 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Phil Terpolilli – Vice President, Investor Relations and Treasury Ron Lombardi – Chairman, President and Chief Executive Officer Christine Sacco – Chief Financial Officer and Chief Operating Officer Conference Call Participants Rupesh Parikh – Oppenheimer Susan Anderson – Canaccord Keith Devas – Jefferies Glenn West – William Blair Anthony Lebiedzinski – Sidoti & Company Doug Lane – Water Tower Research Operator Good day, and thank you for standing by. Welcome to the Prestige Consumer Healthcare's Fourth Quarter 2025 Earnings Conference Call.

Prestige Consumer Healthcare Inc. (PBH) Q4 2025 Earnings Call Transcript

Zacks Investment Research

Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Prestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue Estimates

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.30 per share. This compares to earnings of $1.02 per share a year ago.

Prestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue Estimates

UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025.

UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

See News Rankings

Charts implemented using Lightweight Charts™